-
Napo Pharmaceuticals launches Mytesi
NEW YORK — Napo Pharmaceuticals on Thursday announced the launch of its Mytesi (crofelemer), approved by the Food and Drug Administration as a treatment for non-infectious diarrhea in patients with HIV/AIDS on retroviral therapy. The active ingredient is a plant-based drug extracted from the red bark sap of a tree in the Amazon, for which Napo has set up a sustainable harvesting program.Merck signs value-based contract with Aetna for Januvia, Janumet
HARTFORD, Conn. — Merck and Aetna have entered into a value-based agreement for Merck’s Type diabetes medications Januvia (sitagliptin) and Janumet (sitagliptin plus metformin. The contract will see Merck’s rebates for the drugs based partly on their ability to help Aetna’s commercial members with Type 2 diabetes achieve or maintain treatment goals.